供应商 · 未分类 · 农业生物技术与农业科技
Evogene (NASDAQ: EVGN)
Evogene Ltd.(纳斯达克/特拉维夫证券交易所:EVGN)是计算化学领域的先驱企业,专注于为制药和农业行业进行小分子的生成式设计。 其技术的核心是ChemPass AI——一个专有的生成式人工智能引擎,能够设计在多个关键参数上经过优化的新型高效小分子。这一强大平台显著提高成功率,同时缩短开发时间并降低成本。 建立在这一强大技术基础之上,Evogene通过战略合作与内部产品开发并举,专注于创造由科学创新与真实产业需求融合驱动的突破性产品。公司称之为“真实世界创新”。 了解更多请访问:www.evogene.com。
简介
供应的生物解决方案 0
尚未被列为已评级方案的供应商。
产品与服务
子公司: AgPlenus Ltd. · Biomica Ltd. · Casterra Ag Ltd. · Lavie Bio Ltd.
新闻与状态 6
- 2026-03 最新状态: 公司于2026年3月30日收到纳斯达克关于未满足最低买价要求的通知,并获延期至2027年3月29日以恢复合规。 ↗ ↗ ↗
- 2026-07-08 Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery - EvogeneEvogene is expanding its AI-driven small-molecule drug discovery capabilities through a strategic collaboration with Tel Aviv University’s Blavatnik Center for Drug Discovery to accelerate translational work from Israeli academia, using its ChemPass AI™ …
- 2026-08-31 Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path ForwardEvogene is defending its recent strategic transformation, arguing that its focus on ChemPass AI, six external drug-development agreements, and significant cost reductions have already strengthened its financials and moved the company toward a more …
- 2026-09-30 Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price ComplianceEvogene has received a Nasdaq extension, giving it an additional 180 days (to March 29, 2027) to regain the minimum $1.00 bid price, with continued trading on Nasdaq during the period; if it fails to meet the threshold for 10 consecutive days, it could be …
- 2026-08-18 Evogene Reports Second Quarter and First Half 2026 Financial ResultsEvogene is undergoing a strategic, AI-driven transformation into a lean computational chemistry company focused on generative design of small molecules for pharma and agricultural products, with expanding collaborations and a larger virtual chemical space …
- 2026-07-22 Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases - EvogeneEvogene is partnering with ELEO Inc. to use its ChemPass AI platform for designing and optimizing oral small-molecule inhibitors of the PCSK9 pathway, aiming to accelerate discovery for hyperlipidemia and cardiovascular disease. The collaboration combines …
- 2026-06-24 Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization - EvogeneEvogene announces a major milestone with Google Cloud advancing its ChemPass AI platform toward more autonomous small-molecule discovery and optimization, enabling earlier, richer target profiling and prioritization of high-potential candidates to accelerate …
关系网络:股东、合作伙伴、同类
股权与投资方 6
| 投资方 | ICL Group Ltd |
| 投资方 | Shanghai Healthcare Capital |
| 子公司 | AgPlenus Ltd |
| 子公司 | Biomica Ltd |
| 子公司 | Casterra Ag Ltd |
| 子公司 | Lavie Bio Ltd |
合作与交易 2
| 合作 | Flexible …es, shorten development timelines, and reduce costs.
- Business model: Flexible, blending strategic collaborations with global partners and internal product development to bring computationally …… |
| 合作 | Combines …inable agriculture.
Business approach:
- Combines in-house ChemPass AI capabilities with strategic partnerships to translate AI-generated discoveries into market-ready products.
- Aims to bridge the …… |
同类企业
Kentegra Biotechnology Holdings LLC · Agriventure Egypt · Nawah Scientific · AgriEdge · DeepLeaf · Devgen · Bayer Crop Science Maghreb · Pathorec
身份与联系方式
联系方式、人员和法律信息仅向会员开放。
会员登录